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Abstract: Greenshell™ mussel (GSM, Perna canaliculus) is New Zealand’s most important 16 
aquaculture species. They are a good source of long chain-polyunsaturated fatty acids (n-3 LC 17 
PUFA). Beyond a traditional food product, GSM are also sold as mussel powders and oil extract 18 
formats in the nutraceutical markets. In this study, a four-sequence, single dose, randomized 19 
crossover human trial with eight evaluable healthy male participants was undertaken to determine 20 
the bioavailability of the n-3 LC PUFA in four different GSM formats (oil, powder, food ingredient 21 
and half-shell unprocessed whole mussel) by measuring area under the curve (AUC) and maximal 22 
concentration (CMax). Blood samples were collected at baseline and up to 48 hours after initiation of 23 
product consumption in each administration period. There were minor differences between the 24 
bioavailability of FA between the different GSM formats. Eicosapentaenoic acid (EPA) peak 25 
concentrations and plasma exposures were significantly lower with GSM oil compared to GSM half-26 
shell and GSM powder formats, which resulted in AUC0-48 for the intake of GSM half shell mussel 27 
and GSM powder being significantly higher than that for GSM oil (p=0.013, f= 4.84). This equated to 28 
a 20.6% and 24.3% increase in the amount of EPA present in the plasma after consumption of half-29 
shell mussels and mussel powder respectively compared to GSM oil. GSM oil produced the shortest 30 
median time to maximal plasma n-3 LC PUFA concentration of all evaluated products demonstrated 31 
by a shorter maximum measured plasma concentration (TMax = 5 h). Docosahexaenoic acid (DHA) 32 
and n-3 LC PUFA plasma exposure parameters were statistically comparable across the four GSM 33 
products evaluated. 34 
Keywords: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), Green lipped mussels, Perna 35 
canaliculus, pharmacokinetics, 36 
 37 
1. Introduction 38 
The endemic Greenshell™ mussel (GSM), Perna canaliculus, is New Zealand’s most valuable 39 
aquaculture species in terms of both total value and scale of production. In 2019 the New Zealand 40 
GSM industry produced export revenue of NZ$337M from 30,551tonnes of exported product1. The 41 
majority of GSM export sales (>80%) are presently sold as frozen half-shell food products. However, 42 
there has been recent significant growth in nutraceutical powder and oil product production, with 43 
sales of NZ$45.7 M in 2018 equivalent to a 334% increase in the last 8 years. These nutraceuticals 44 
command high prices, with oil extracts selling for ca. NZ$1,900 per kg (in 2018) as opposed to freeze-45 
 
dried mussel powders ca. NZ$45 per kg. Furthermore, the industry is actively working to develop 46 
novel food ingredients for use in a variety of different food formats, to reach markets where live and 47 
frozen GSM cannot penetrate.  48 
To the best of our knowledge GSM oil is the most valuable marine oil (by price) in the world, 49 
sitting presently at over $1300 USD/kg1. The GSM lipid fraction contains a high proportion of omega-50 
3 long-chain (C ≥ 20) polyunsaturated fatty acids (n-3 LC PUFAs), predominantly (DHA, 22:6n-3) and 51 
eicosapentaenoic acid (EPA, 20:5n-3), which are split between the triacyglycerol (TAG) and polar 52 
lipid (PL) classes 2, 3. These GSM products have been extensively tested in pre-clinical animal studies 53 
4, 5. A recent review has identified a gap in the literature for GSM active ingredients regarding their 54 
pharmacokinetics and identification of the bioactive factors responsible for each observed therapeutic 55 
effect4.  56 
The health benefits of n-3 LC PUFA , such as DHA and EPA, have been extensively studied and 57 
found to include anti-inflammatory activity, maintenance of normal heart function and lipid profile, 58 
and hypertriglyceridemia management6-9. Due to these health benefits, n-3 LC PUFA enriched 59 
materials have been widely used in functional foods and nutritional supplements 10-12. However, there 60 
are challenges in evaluating efficacy of n-3 LC PUFA in delivering health benefits7 as the digestion of 61 
lipophilic components of foods and nutritional supplements is subject to a complex series of processes 62 
including bile salt emulsification and pancreatic lipase hydrolysis 13. Account must be taken of the 63 
considerable variability in the absorption of different n-3 LC PUFAs, as well as the format they are in 64 
(i.e. lipid class) which may have a direct impact on their bioactivity12, 14.  65 
Nutraceutical products from GSM (both oil and powders) have been shown to have benefits in 66 
human clinical trials on the alleviation of osteo-/rheumatoid-arthritis15-17, asthma18, 19, and adverse 67 
effects of exercise and/or inflammation20, 21. With some new animal studies showing novel activity in 68 
protecting against cartilage damage in both early-stage and late-stage metabolic osteoarthritis5, 69 
increasing lean mass accrual in diet-driven obesity, and reducing loss of bone mineral density in 70 
osteoporosis22. Due to the low lipid content of mussels (~2%), nutraceutical oils from GSM are 71 
produced on an industrial scale either by solvent extraction or by supercritical CO2 extraction. Freeze- 72 
and spray-drying are the most commonly utilised methods for producing GSM powders, which are 73 
utilised as nutraceuticals and are being developed as food ingredients. It has been identified that in 74 
these GSM nutraceutical studies using animal and clinical models there were inconsistencies in the 75 
degree of benefit provided, which could be attributed to the different dosages used and the different 76 
types of GSM extracts used4. In turn, these differences could affect the concentrations of key 77 
bioactives present.  78 
The bioavailability and pharmacokinetics (PK) of a drug are key determinant factors in the 79 
ultimate manifestation of efficacy in clinical practise. The same applies to bioactives from natural 80 
sources that deliver health benefits such as n-3 LC PUFA. Critically important parameters are the 81 
CMax (Maximum measured plasma concentration from time), TMax (Time of the maximum measured 82 
plasma concentration), elimination t½, and AUC (incremental area under the plasma concentration-83 
time curve) data after single and multiple doses, which are used to determine optimum dosing 84 
regimens. Various biomarkers (such as EPA and DHA) have been used in recent studies on the 85 
bioavailability of n-3 LC PUFA , but their effectiveness has not been systematically compared nor has 86 
their use been fully justified 10, 11, 14, 23-25. In addition, there is growing evidence that the bioavailability 87 
of n-3 LC PUFAs varies depending upon their derived sources, such as krill oil, fish oil, mussel or 88 
algal oils 10-12, and is further dependent on the fat composition and content of the diet and the food 89 
preparation methods employed 10, 26. This is due to the food structure or format of the n-3 LC PUFAs 90 
of the difference sources. The difference in the bioavailability of n-3 LC PUFAs when eaten as food 91 
product, functional food, freeze dried powder and/or extracted oil is yet to be established and we 92 
hypothesise that may differ as food structure and therefore digestion may be effected by format. In 93 
this paper, pharmacokinetic parameters to determine bioavailability (CMax, TMax and AUC) of n-3 LC 94 
PUFA were measured for different formats of GSM following single dose intakes, as a first step in 95 
gaining a better understanding of the pharmacokinetics of key active ingredients. 96 
There are 40 years of scientific literature connecting GSM extracts with health benefits; however, 97 
there are major knowledge gaps preventing validated health claims, particularly around consistent 98 
 
efficacy and proven bioavailability. This study was intended to evaluate comparative 99 
pharmacokinetics and bioavailability of orally administered bioactive compounds from whole 100 
mussels, nutraceutical products and a novel functional food ingredient. A four-sequence, single dose, 101 
randomized crossover study in healthy adults was undertaken to determine the bioavailability of n-102 
3 LC PUFAs, EPA and DHA in different GSM formats (Frozen half-shell GSM, GSM Food ingredient, 103 
GSM Powder and GSM Oil extract). Blood samples were collected pre-dose and up to 48 hours with 104 
2-hour intervals in the initial 8 hours and 4-8 hour intervals in the later stage after initiation of product 105 
administration. The aim of this study was to assess the uptake and retention of the n-3 LC PUFA by 106 
healthy adults from the four different formats.  107 
2. Results 108 
A total of twelve subjects were screened for the study. One subject failed screening based on an 109 
exclusionary BMI. Two further subjects met eligibility criteria at screening but subsequently 110 
withdrew consent prior to study enrolment. 111 
Nine subjects were randomized into the study and were included in the safety population. This 112 
included one subject (subject 04) who withdrew consent prior to completing PK sampling for 113 
Administration Period 1; a replacement subject (subject 14) was randomised into the study, to ensure 114 
eight evaluable subjects.  115 
All subjects in the safety analysis set identified their ethnicity as European (7 New Zealand 116 
European, 1 Spanish, 1 European). The mean age of subjects was 23 years (range 20 – 30 years), with 117 
mean BMI 24.4 kg/m2 (range 21.5-30.7 kg/m2).  118 
The mean plasma concentrations of EPA, DHA and total n-3 PUFA (all omega 3 fatty acids 119 
including α-linolenic acid (ALA, 18:3n-3), stearidonic acid (SDA, 18:4 n-3), eicosatetraenoic acid (ETA 120 
20:4, n-3), EPA, docosapentaenoic acid (DPA,22:5 n-3) & DHA) after a single dose of the four GSM 121 
products are shown in figures 1-3 respectively. Two distinct periods identified and analysed for AUC, 122 
CMax and TMax which were the periods between 0-12 h and the whole period (0-48h) (Tables 1- 3). The 123 
values in table 1-3 are calculated from the raw plasma concentrations which are not corrected for 124 
wide variations in the baseline values which are reported in Figure 1-3. Figures 1-3 which gave been 125 
baseline adjusted.   126 
There were significantly (p=0.013, f= 4.84) higher AUC in EPA concentrations with the GSM half 127 
shell mussel and GSM powder compared to the GSM oil over the 48-hour period (Table 1). However, 128 
there were no differences in the EPA in the shorter 0-12h range. In the DHA and the n-3 LC PUFA 129 
there were no statistical differences between treatments in the AUC over either of the different time 130 
periods.  131 
The CMax0-12h and CMax0-48h were significantly (p=0.011, f= 5.05 & p=0.004, f=6.39 respectively) higher 132 
in the EPA of the GSM half shell compared with GSM food ingredient and GSM oil over both time 133 
periods. Further, the CMax0-12h and CMax0-48h of the GSM powder were significantly different (p=0.011, f= 134 
5.05 & p=0.004, f=6.39 respectively) between the GSM powder and the GSM oil.  135 
There were no statistical differences determined in the CMax0-12h and CMax0-48h in DHA and n-3 LC 136 
PUFA concentrations during the study.  137 
The TMax0-48h was significantly (p=0.04) lower (5h) in the GSM oil than the other three formats (in 138 
the 24-27 range) but this was not evident in the shorter TMax0-12h period. Two peaks are identified 139 
(figure 1-3) in the concentration-time profiles which led to two time periods analysed for maximum 140 
measured plasma concentration (0-12h and 12-48h). There were no statistical differences determined 141 
in the TMax0-12h and TMax0-48h in EPA and DHA concentrations during the study.  142 
All evaluated GSM food platforms were well tolerated. A total of three subjects (33.3%) 143 
experienced a total of three adverse events (AEs). Two AEs (dry throat and upper respiratory tract 144 
infection) were considered unrelated to test product; the remaining AE of a headache was considered 145 
by the Investigator to have a remote relationship to test product. The three reported AEs were graded 146 
as mild in severity, required no specific intervention, and resolved spontaneously. No deaths, serious 147 
AEs, or AEs resulting in discontinuation of study product were reported.  148 
 149 
 
 150 
Figure 1. Mean (+SD) eicosapentaenoic acid (EPA) concentration-time profiles (baseline-adjusted 151 
change) after a single dose of Frozen half-shell GSM, GSM Food ingredient, GSM Powder and GSM 152 
Oil extract with matching levels of lipid. 153 
 154 
 
Figure 2. Mean (+SD) docosahexaenoic acid (DHA) concentration-time profiles (baseline-adjusted 155 
change) after a single dose of Frozen half-shell GSM, GSM Food ingredient, GSM Powder and GSM 156 
Oil extract with matching levels of lipid. 157 
 158 
Figure 3. Mean (+SD) n-3 LC PUFA (>18 carbon length) concentration-time profiles after a single dose of 159 
Frozen half-shell GSM, GSM Food ingredient, GSM Powder and GSM Oil extract with matching levels of 160 
lipid161 
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Table 1. Plasma content of the pharmacokinetic parameter, AUC (area under the plasma concentration-time curve) for eicosapentaenoic acid (EPA), docosahexaenoic 162 
acid (DHA), and long chain-polyunsaturated fatty acids (n-3 LC-PUFA) after a single dose of Frozen half-shell GSM, GSM Food ingredient, GSM Powder and GSM Oil 163 
extract with matching levels of lipid at 12 and 48 hour time points. a,bGeometric means values across the column not sharing a common superscript were significantly 164 
different (p < 0.05) as determined by Fisher’s protected LSD 165 
 AUC0-12 h           
 
 
AUC0-12h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
AUC0-12h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
AUC0-12h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
Frozen half-shell GSM 
EPA 
5407.0 4375.7 6681.5 
DHA 
8819 7457 10429.9 
n-3 
LC 
PUFA 
17880.3 16250.7 19673.4 
GSM Food ingredient 5046.2 3722.2 6841.2 8840.1 7570.1 10323.2 18071.9 15091.8 21640.5 
GSM Powder 5821.7 4395.8 7710.3 7947.8 6771.1 9328.9 18180.9 15760.3 20973.3 
GSM Oil extract 4886.9 4137.2 5772.3 8340.8 7350.8 9464.0 17305.3 15516.0 19300.8 
F -    -    -    
p-value -     -     -     
            
 AUC0-48h           
  
AUC0-48h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
AUC0-48h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
AUC0-48h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
Frozen half-shell GSM 
EPA 
23963.6b 19489.7 29464.6 
DHA 
34167.4 28805.8 40526.9 
n-3 
LC 
PUFA 
73793.4 65863 82678.8 
GSM Food ingredient 22138.7a,b 17126.5 28617.8 34549.4 30361.7 39314.6 74412.4 63442.4 87279.2 
GSM Powder 24683.2b 18464.3 32996.6 32574.5 27579.2 38474.6 75639.8 62800.7 91103.7 
GSM Oil extract 19858.4a 16821.8 23443.2 32194.5 28017.1 36994.9 68033.5 60115.2 76994.7 
F 4.840    -    -    
p-value 0.013     -     -     
 
Table 2. Plasma content of the pharmacokinetic parameter CMax (Maximum measured plasma concentration over the time span specified) for eicosapentaenoic acid 166 
(EPA), docosahexaenoic acid (DHA), and long chain-polyunsaturated fatty acids (n-3 LC-PUFA) after a single dose of Frozen half-shell GSM, GSM Food ingredient, GSM 167 
Powder and GSM Oil extract with matching levels of lipid for 12 and 48 hour time points. a,b,c Geometric mean values across the column not sharing a common 168 
superscript were significantly different (p < 0.05) as determined by Fisher’s protected LSD. 169 
 CMax0-12h            
  
CMax0-12h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
CMax0-12h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
CMax0-12h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
Frozen half-shell GSM 
EPA 
546.6c 441.4 676.9 
DHA 
851 747.8 967.3 
n-3 LC 
PUFA 
1694 1578.5 1818.5 
GSM Food ingredient 474.4a,b 359.7 625.7 834 724.1 959.3 1681 1439.6 1961.9 
GSM Powder 539.0b,c 405.7 716 736 640.2 845.5 1659 1434 1918.5 
GSM Oil extract 450.4a 372.1 545.1 780 711.2 855.6 1604.5 1414.2 1820.9 
F  5.045    -    -    
p-value  0.011     -     -     
             
 CMax48h            
  
CMax0-48h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
CMax0-48h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
 
CMax0-48h 
mg/L 
95.0% 
Lower CL 
for Mean 
95.0% 
Upper CL 
for Mean 
Frozen half-shell GSM 
EPA 
594.7c 499.8 707.5 
DHA 
857 759.2 968.4 
n-3 LC 
PUFA 
1772 1623.6 1934 
GSM Food ingredient 536.8a,b 421.5 683.7 852 749.1 968 1782 1509.3 2103.4 
GSM Powder 593.3b,c 445.5 790.2 835 703.6 992 1832 1504.6 2230.6 
GSM Oil extract 477.4a 395.1 576.8 806 713.9 909.2 1634 1431.5 1864.7 
F 6.388    -    -    
p-value 0.004     -     -     
Table 3. Plasma content of the pharmacokinetic parameter TMax (Time of the maximum measured plasma concentration over the time span specified) for eicosapentaenoic 170 
acid (EPA), docosahexaenoic acid (DHA), and long chain-polyunsaturated fatty acids (n-3 LC-PUFA) after a single dose of Frozen half-shell GSM, GSM Food ingredient, 171 
GSM Powder and GSM Oil extract with matching levels of lipid for 12 and 48 hour time points. a,b Arithmetic mean values across the column not sharing a common 172 
superscript were significantly different (p < 0.05) as determined by Friedman’s Two-Way Analysis of Variance by Ranks 173 
 TMax12h            
  
TMax  
(0-12h) 25 
percentile 
TMax  
(0-12h) 
Median 
TMax  
(0-12h) 75 
percentile 
 
TMax  
(0-12h) 25 
percentile 
TMax  
(0-12h) 
Median 
TMax  
(0-12h) 75 
percentile 
 
TMax  
(0-12h) 25 
percentile 
TMax  
(0-12h) 
Median 
TMax  
(0-12h) 75 
percentile 
Frozen half-shell GSM 
EPA 
6 6 8 
DHA 
2 4 6 n-3 LC 
PUFA 
6 6 8 
GSM Food ingredient 6 6 6 2 3 5 3 5 6 
 
GSM Powder 5 6 7 4 4 6 4 5 7 
GSM Oil extract 5 6 6 4 4 5 4 5 6 
F  -    -    -   
p-value  -    -    -   
               
 TMax48h            
  
TMax 
(0-48h) 25 
percentile 
TMax 
 (0-48h) 
Median 
TMax  
(0-48h) 75 
percentile 
 
TMax 
(0-48h) 25 
percentile 
TMax 
 (0-48h) 
Median 
TMax  
(0-48h) 75 
percentile 
 
TMax 
(0-48h) 25 
percentile 
TMax 
 (0-48h) 
Median 
TMax  
(0-48h) 75 
percentile 
Frozen half-shell GSM 
EPA 
12 24 24 
DHA 
2 4 6 
n-3 LC 
PUFA 
12 24b 48 
GSM Food ingredient 24 30 30 2 4 6 15 27b 48 
GSM Powder 24 24 30 4 29 48 24 30b 41 
GSM Oil extract 5 15 24 4 4 18 4 5a 16 
F  -    -    -   
p-value  -    -    0.04   
 174 
 
3. Discussion 
In this study we measured the pharmacokinetic parameters (AUC, CMax and TMax) for the bioactive 
n-3 LC PUFA in human subjects fed different forms of GSM. Two time periods were analysed as there 
were two distinct peaks in the bioavailability of these bioactive lipids (Figure 1-3). These two distinct 
periods have been previously reported in a high PL n-3 LC PUFA bioavailability study27. The whole 
48h period pharmacokinetic parameters were determined as well as the shorter 0-12h (table 1-3). These 
two time periods allowed for good comparison with published literature results (most of which were 
over the 0-12 h period) and also extrapolation with longer-term studies. This research addresses the 
essential step in understanding the bioavailability of key bioactives (n-3 LC PUFA) in GSM formats. 
The lack of bioavailability data in the literature for GSM, in both animal and clinical models, has 
enhanced inconsistencies with the efficacy data and makes comparisons between trials/formats 
difficult.  
The results showed differences only in the bioavailability of EPA in the GSM half shell mussel and 
GSM powder compared to the GSM oil over the 48-hour period with significant (p = 0.013, f = 4.84) 
differences in the AUC0-48t (table 1). This corresponds to a 20.6% and 24.3% increase in the amount of 
EPA present in the plasma after consumption of half-shell mussels and mussel powder respectively. 
The GSM food ingredient had a similar bioavailability of EPA to the GSM half shell and GSM powder 
products but was not significantly different to that of the GSM oil. In the DHA and n-3 LC PUFA there 
were no differences determined between the four different GSM formats.  
The CMax of EPA was significantly lower for the GSM oil than the GSM half-shell and GSM powder 
formats in both the 0-12h and 0-48h time frames (table 2). Further there was a significant difference in 
CMax between the GSM half shell mussels and the GSM food ingredient for both time periods. This 
relates to a 22-25% increase in EPA in the plasma if delivered as a GSM half shell and GSM powder 
compared to extracted GSM oil depending on the timeframe calculated. The extracted oil (GSM oil) had 
a significantly shorter time (5 h) to reach the time of the maximum measured plasma concentration TMax 
of n-3 LC PUFA than the other three formats, which were between 24-30h only when assessed over the 
48h period (table 3).  
The data (shown in the tables) were not baseline-adjusted due to the fact that many of the adjusted 
AUCs were negative for all formats and therefore it was not possible to analyse these with the 
transformed ANOVA models. However, the figures were all adjusted to account for differences in 
baseline levels of omega 3. Further we intended to calculate half-life (t½) of the n-3 LC PUFA but the 
plasma levels did not equalise to baseline in 48h and stayed high for the duration of the study, and 
therefore the calculation was not possible. The t½ is an important kinetic parameter and is worthy of 
mention due to the longevity of the key actives in the plasma, which could indicate one or two feeds a 
week would provide elevated levels of n-3 LC PUFA. 
Different food formats will deliver n-3 LC PUFA in different molecular forms. In this study, we 
attempted to match the lipid content (2.2 ± 0.1 g/100g) across the four formats with only the food 
ingredient (2.05 g/100g) not meeting that requirement (table 4). However, the lipid classes and the 
amount of n-3 LC PUFA were different. The GSM oil and frozen half shell mussels were predominately 
in the form of PL (64% and 68% respectively), whilst the food ingredient and the mussel powder were 
mainly TAG (97% and 94% respectively). EPA was consistent across the four diets (341 ± 15 mg/100g); 
however, the DHA content was markedly different. The frozen half shell mussels had the highest 
content of DHA (311 mg/100g) followed by the oil (267 mg/100g), then the two powders (174 & 189 
mg/100g for the food ingredient and mussel powder respectively). These differences in content 
contributes uncertainty to our results but using natural and food products as a part of a clinical trials it 
is hard to get interventions that are uniform in composition due to natural variation in these products.  
The GSM oil and particularly the GSM half shell mussel formats were abundant in these 
phospholipids (identified in this paper as PL), but there has yet to be a lipidomic profile determining 
the phospholipid profile of GSM published. PL has the capability to act as an emulsifier, enhancing the 
formation of lipid extract emulsion in the digestion. In general, in marine oils the more unsaturated 
 
fatty acids are most likely to attach to the sn2-position. It has been shown in GSM that EPA is more 
abundant in the TAG fraction than the PL fraction when extracted chemically (the opposite was shown 
in supercritical extracted fraction albeit the PL fraction was a very minor part of that oil)2. However 
there was no statistical difference in the concentration of DHA across the non-polar and polar fractions2. 
The PL fraction has been reported to be the predominant lipid across 12 months of sampling in the GSM 
production areas, and n-3 PUFAs were consistent across the seasons with 35-38% of all fatty acids 
primarily made up of EPA and DHA3. Further analysis has shown that there are differences in the 
concentrations of EPA (but not DHA) dependent on gender (with females having 43% more EPA than 
males) as well as significant differences in the lipid classes (with PL lower and TAG greater in female 
mussels)28. In this study we only use female mussels to reduce the impact of these gender differences. 
Both the GSM powder and GSM food ingredient have been processed to form these products (e.g. 
homogenising, drying etc.) and through this process the PL fraction of the lipid profile was minor (see 
table 4). Therefore, the bioavailability of EPA and DHA in GSM, independent of format, may be affected 
by factors such as season, extraction method, processing method and gender of mussels due to 
structural and concentration changes of the bioactive FA and these may account for some of the 
differences we have shown in this study as well as discrepancies in the published literature.  
There have been minimal and conflicting studies comparing the bioavailability of EPA and DHA 
when delivered in different food formats, e.g. oil in a capsule verses fish as a meal. Visioli et al.29 showed 
increased levels of plasma EPA and DHA when they fed salmon compared to capsules but attributed 
their finding to the larger fat content of the meal. They concluded that fish is more effective than 
capsules in providing n-3 LC PUFAs. Elvevoll et al.30 showed fish consumption is more effective in 
increasing serum EPA and DHA than supplementing the diet with fish oil. In contrast, Stonehouse et 
al.31 showed salmon oil or fillets were equally effective in delivering n-3 LC PUFA; however, there was 
additional benefit of increased levels of plasma selenium in the healthy volunteers who ate the fish. 
Finally, Harris et al. 32 determined there was no difference between oily fish (2 servings of oily fish e.g. 
salmon and albacore tuna per week) and fish-oil (1-2 capsules per day) on enriching blood lipids with 
n-3 FA.  
Our GSM formats were all consumed with a low-fat soup meal (see section 4.1) to reduce influence 
of breakfast/food has on the intake of n-3 LC PUFA. It has been shown that the lipid content of a meal 
in postprandial studies such as a high fat breakfast can influence plasma omega 3 levels 33. Diet was 
restricted of n-3 LC PUFA and standardised over during the clinic visits with further diet, medication 
and lifestyle restrictions that applied over the duration of the study (see section 4.3 for details).  
Our results show that there is a slight but significant GSM format-dependent increase in AUC0-48h, 
CMax and TMax0-48h for EPA but not DHA or n-3 LC PUFAs. Our results do not conclusively answer the 
differences in food formats on the bioavailability of EPA and DHA and acknowledge the format of the 
EPA (whether on the position on the glycerol backbone or in the lipid class) may play a vital role in its 
bioavailability. We provided the food in a form of a soup to reduce the effect of a large fat content of 
the meal as a pervious study29 indicated this may be an confounding factor. However due to the nature 
of all the food products delivering n-3 LC PUFA through different lipid classes (e.g. TAG or PL), 
metabolic fates would be different, and comparisons are not identical.  
There are limitations of the trial which are worthy of discussion. Firstly, participants were not 
screened for intake of n-3 LC PUFA prior to the trial and therefore bioavailability results may be 
different in individuals who have a high baseline n-3 LC PUFA status. Sample size is also a limitation 
however this is an exploratory study and the small sample size is sufficient to assess these fatty acid 
pharmacokinetic parameters. Future studies may want to consider a longer wash out period between 
administration and a study length of greater than 48 hours. A two week wash out would be preferable 
as some LC-PUFA, particularly as DHA concentrations appear to be still increasing at 48 hours and the 
14-day wash will achieve a better chance to return to baseline.  
Reviews of short-term post-prandial studies have reported that the type of lipid has implications 
on the bioavailability33, 34. The bioavailability of EPA and DHA in the ethyl ester form (EE, a synthetic 
form commonly used for nutraceutical lipids and particularly used in concentrated delivery systems) 
 
were significantly lower than in TAG29. Further complexity occurs when comparing PL and TAG forms, 
as the literature suggests that these lipid classes are metabolised via different mechanisms and possibly 
have different fates. It has been shown that labelled 13C DHA in the PC form has a markedly different 
kinetics and metabolic fate compared to TAG35. A recent review of human clinical trials found no 
conclusive evidence that the bioavailability of n-3 LC PUFA was greater from PL versus TAG sources; 
however there was some evidence of increase bioavailability of n-3 LC PUFA delivered as PL in animal 
models34.  
In this trial the different delivery formats had differing proportions of TAG and PL. Both the GSM 
oil (94%) and GSM half shell (68%) were predominantly PL, whereas the opposite was true for the GSM 
powder (92% TAG) and GSM food ingredient (95% TAG). However, the differences we demonstrated 
in the EPA in AUC, TMax and CMax were seen between the GSM oil and GSM half shell, which had similar 
lipid class profiles. Further, the GSM powder and GSM oil, which have opposite lipid class profiles, 
had significantly different pharmacokinetic profiles in regard to EPA. This evidence suggests that lipid 
class can play a role in the bioavailability of FA from GSM.  
Experimental and human studies with GSM now span some 40 years, and although animal 
veterinary and clinical trials have been conducted in the last 15 years there is still considerable inter-
study variation in the ingredients and dosages used. Sound QA on raw materials and formulations of 
GSM ingredients have been lacking as well as poor understanding of absorption, bioavailability, 
distribution, metabolism, and excretion of key active ingredients. As our understanding on the key 
active ingredients in GSM extracts improves, analytical methodology can be used to assess the 
concentration of these bioactives in GSM foods, extracts, and final product. This will open up new 
research avenues as more pharmacokinetic studies become a possibility. It will also allow GSM 
breeding programmes to select for mussel families that produce higher levels of the bioactives of 
interest, with good bioavailability yielding a more potent feedstock for therapeutic usage in animals 
and humans alike. This single dose trial has provided early insights which will need to be 
complemented by multi-dose trials in clinical settings to further establish the bioavailability and 
pharmacokinetics of GSM bioactive components.  
In summary, the AUC, CMax and TMax of EPA were affected by the delivery format. This may be 
related to EPA’s positions on the glycerol backbone as well as the processing procedures. The evidence 
suggests that lipid class (PL or TAG format) plays a role in the bioavailability of EPA. EPA has 
previously been shown to be more bioavailable in terms of TMax than DHA12. TMax for EPA and DHA is 
in the range 2 h-24 h, which may be related not only to their molecular chains and bonding structure, 
but also to the format by which they were delivered. In our study we were able to show there were no 
differences in DHA or n-3 LC PUFA in terms of AUC, CMax and TMax in any of the four GSM formats.  
4. Materials and Methods  
4.1 GSM food formats 
Four food formats were prepared to match in lipid content (table 4)  
1. Frozen half-shell GSM - 125 g Sanford (Blanched GSM, Orvida brand, Sanford, Havelock NZ, 
Lot # M177812907, production date 9 May 2018) 
2. GSM Food ingredient - 22.5 g Sanford (Batch L001, production 25 March 2018)  
3. GSM Powder - 22.5 g Enzaq (Batch L457-2, production 08 July 2018) 
4. GSM Oil extract - 2.3 g Pernatec oil (Waitaki Bioscience, production date 5 May 2018)  
All samples were aliquoted and kept frozen until administration during the trial period of 31 July 
– 24 September 2018. The food ingredient is an activated GSM powder product developed to be utilised 
in the incorporation of functional foods.  
To control for the effects of whole-meal components, all four GSM products were served in the 
same format, a leek and potato soup (204.3g per portion) comprised of the ingredients; 600g Leeks, 250, 
Onions, 5g Garlic, 30g unsalted butter, 350 g Potato (agria), 600 g Chicken stock, 2g Bay leaf, 0.2g 
Thyme, 1 tsp Iodised salt, Ground black pepper and 200ml low fat milk. The study was conducted from 
 
31 July – 24 September 2018 at the Christchurch Clinical Studies Trust Ltd (CSST) site in Christchurch, 
New Zealand. The study was approved from the Central Health and Disability Ethics Committee 
(18/CEN/120) and conducted in accordance with ICH GCP and local ethical and regulatory 
requirements. 
Table 4. Composition of the four samples (Frozen half-shell GSM, GSM Food ingredient, GSM Powder 
and GSM Oil extract) fed to clinical trial participants. 
 
GSM Oil 
extract 
Frozen 
half-shell 
GSM 
GSM Food 
ingredient 
GSM 
Powder 
Sample size (g)  2.3 125 22.5 22.5 
     
Proximate composition Amount per serving (g) 
Fat 2.30 2.25 2.05 2.23 
Ash 0.00 1.75 4.82 3.94 
Crude Protein 0.00 17.79 11.12 10.44 
Carbohydrate 0.00 5.25 3.85 5.06 
  
Fatty acid profile Amount per serving (mg) 
C14:0 myristic acid 111.3 97.5 81.8 87.1 
C16:0 palmitic acid 326.2 289.4 308.0 348.4 
C16:1 palmitoleic acid 146.5 128.1 137.5 151.5 
C18:0 stearic acid 84.0 88.6 69.6 92.8 
C18:1n7 vaccenic acid 58.6 50.4 50.5 64.4 
C18:1n9c oleic acid 48.8 21.7 24.4 24.6 
C18:2n6c linoleic acid 84.0 39.5 40.0 32.2 
C18:3n3 alpha linolenic acid (ALA) 25.4 26.1 27.8 17.6 
C18:3n4 octadecatrienoic acid 23.4 21.0 2.6 2.5 
C18:4n3 stearidonic acid (SDA) 48.8 58.0 47.0 32.2 
C20:1 gadoleic acid 37.1 31.2 36.5 41.7 
C20:4n6 arachidonic acid (AA) 33.2 27.4 29.6 26.5 
C20:5n3 eicosapentaenoic acid (EPA) 355.5 350.0 339.4 320.0 
C22:5n3 docosapentaenoic acid (DPA) 25.4 23.6 24.4 28.4 
C22:6n3 docosahexaenoic acid (DHA) 267.6 311.1 174.0 189.3 
∑SFA 554.1 509.8 493.4 567.8 
∑MUFA 291.0 234.7 251.5 285.3 
∑PUFA 879.5 880.5 718.3 684.8 
∑Omega 3 727.9 776.0 622.2 595.7 
∑Omega 6 140.6 91.5 77.4 69.7 
     
Lipid class Amount per serving (mg) 
Polar lipids (PL) 1463.6 1530.0 14.3 46.8 
Sterols 29.9 104.3 43.0 82.4 
Triacylglycerols (TAG) 801.9 622.5 1951.3 2051.5 
 
∑SFA includes C15:0 pentadecanoic acid, C17:0 heptadecanoic acid, C20:0 arachidic acid and C21:0 heneicosanoic 
acid. ∑PUFA include C16:2n4 hexadecadienoic acid, C18:3n6 gamma linolenic (GLA), C20:3n3 cis-11, 14, 17-
eicosatrienoic acid, C20:3n6 cis-8, 11, 14-eicosatrienoic acid and C20:4n3 eicosatetraenoic acid.. 
4.2 Clinical study  
The study was designed as an open-label, randomized, four-sequence crossover trial in eight 
evaluable healthy adult male participants. Administration occurred over the course of four 
administration periods, with a wash-out of at least seven days between test products. 
The open-label, randomized cross-over design was utilised to enable both intra-subject and inter-
subject comparison. No formal sample size calculations were made for this study, however the sample 
size of eight was expected to be adequate for evaluation of the parameters of interest. Single exposure 
pharmacokinetics allowed adequate characterization of the performance of each product and was 
therefore appropriate in meeting the study objective.  
The dose of each product was selected to have similar lipid content (2.2 ± 0.1g). Products were 
tested by the accredited Cawthron food testing laboratory, to determine accurate lipid and fatty acid 
content. The one-week washout interval utilised in the current trial was based on a previous study36. 
Key study inclusion criteria limited the study to healthy adult males aged 18 – 45 years, body mass 
index (BMI) 18 to 32 kg / m2 inclusive, with no clinically significant medical conditions. The study 
population was selected to reduce inter-subject variability and is considered appropriate for a non-
therapeutic trial assessing pharmacokinetic parameters. 
All subjects were provided with written and oral information about the study prior to the 
screening visit. Subjects were required to sign and date the most current Independent Ethics Committee 
(IEC)-approved written informed consent form before any study specific assessments or procedures 
were performed. 
Potential subjects underwent screening procedures up to 28 days before the Day 1 of the first 
assessment period, to evaluate their eligibility for the study. Demographics, relevant medical history, 
and medication history were recorded. Subjects underwent a complete physical examination. Body 
weight, height (and derived BMI), vital signs and a single 12-lead electrocardiogram (ECG) were 
recorded. Blood and urine samples were collected for laboratory safety tests (haematology, 
biochemistry, urinalysis). A urine drug screen and breath alcohol tests were performed.  
Following screening procedures, eligible subjects were enrolled into the study and completed four 
administration periods at the CCST research unit. For each subject, product administration order was 
determined by randomized allocation to one of four Test Product sequences.  
Each administration period comprised a long clinic visit (from approximately 1½ hours prior to 
product administration through until completion of 12-hour post-administration assessments) and 
several short visits.  
During each Administration Period PK samples were collected pre-dose and 2, 4, 6, 8, 12, 24, 30, 
34 and 48 hours after initiation of product administration, for measurement of plasma EPA, DHA and 
n-3 LC PUFA. Blood samples were centrifuged at 4000 rpm (1520g) at 4°C for 10 min and the plasma 
was taken and stored at -80oC, cryopacked and shipped to Cawthron Institute for analysis.  
Subjects were discharged from the study on completion of the final administration period 
assessments. Total study duration for each subject was up to approximately 90 days. Figure 4 gives an 
overview of the study design. 
  
 
 
 Day  Day  Day  Day   
 1 2 3  1 2 3  1 2 3  1 2 3   
                  
                  
                  
                  
Screening 
Window a 
Administration 
Period 1 
Administration 
Period 2 
Administration 
Period 3 
Administration 
Period 4 
End of 
Study b 
     
 = Clinic visit for Test Product administration and assessments (through to 12 hours post dose) 
 
 = Clinic visit(s) for blood sampling (at 24, 30, 34 and 48 hrs post dose) 
   
 = Washout Period (at least seven days between administration of each Test Product) 
   
Figure 4. Study Design: (a) Up to 28 Days prior to Day 1 of Administration Period 1 (b)On 
satisfactory completion of all Administration Period 4 procedures  
4.3 Protocol Restrictions 
Dietary, medication and lifestyle restrictions were applied during the study. At each visit subjects 
were reminded of the study restrictions and each subject’s compliance was assessed. Restrictions were 
as follows: 
 No prescription or over-the-counter medications, vitamins, minerals, or herbal 
supplements were permitted, from 2 weeks prior to first test product administration until 
study completion. Although medications required to treat adverse events were 
permissible with approval from the Investigator, no concomitant medications were used 
by any subjects during the study. 
 Consumption of fish or other seafoods, or fish/seafood-containing products was not 
permitted, from two weeks prior to first test product administration until study 
completion. 
 A fat-controlled diet was required, from 1 week prior to first test product 
administration until study completion.  
Standardised meals were provided during long clinic visits, with no other food permitted.  
 Alcohol was not permitted, from 48 hours prior to each test product administration 
until the final PK sample collection in each administration period. A negative alcohol 
breath test was required at screening and prior to test product administration. 
 Consumption of cigarettes or other nicotine-containing products was not permitted, 
from screening until study completion. 
 Recreational drug use was not permitted, from screening until study completion. A 
negative urine drugs of abuse screen was a requirement for study entry. 
 Water was not permitted, for one hour pre- and post- test product administration. 
Water was otherwise permitted ad libitum. 
4.4 Assessment of Safety 
 
Clinical laboratory tests and electrocardiograms were performed at screening only, to confirm 
study eligibility. Tolerability during the study was assessed by monitoring adverse events (AEs) and 
vital signs (recorded pre-dose and 12-hours post-dose in each Administration Period, and prior to 
discharge from the study). 
4.5 Lipid analysis 
Plasma was defrosted (500µL aliquot) and 250µL cold isotonic saline (0.9%) and 1ml isopropanol 
(containing 0.005% BHA as an antioxidant) were added and vortexed thoroughly. Chloroform (2ml, 
containing 0.005% BHA as an antioxidant) was added and mixed thoroughly for 10 min. The samples 
were centrifuged at 3000 rpm (850g) at 4oC for 10min. The bottom organic phase was sampled and 
concentrated under nitrogen prior to methylation. The sample was trans-methylated in methanol: 
chloroform: hydrochloric acid (10:1:1, v/v/v) for 1 h at 100oC. After addition of water the mixture was 
extracted three times with hexane: chloroform (4:1, v/v) to obtain fatty acid methyl esters (FAME). 
Samples were made up with 200µL Hexane with an internal injection standard (C19:0 methyl 
nonadecanoate; NuCheck Elysian, MN, USA). 
FAME samples were run in accordance to AOAC official methods 963.22 (“Methyl Esters of fatty 
acids in oils and fats”). In brief, FAME was analysed by gas chromatography (GC) performed using an 
Agilent 6890 with an Agilent SP-2560 silica capillary column (100m x 0.25 mm i.d., 0.2 µm film 
thickness) and peak area determined by flame ionised detection (FID). Samples (1 µL) were injected via 
a split injector at 260oC. The column temperature programme was: 220oC at 17 min, then raised by 
2.8oCmin-1 to 240oC and held for 5 min. Fatty acids were identified to an external commercial fatty acid 
standard (Supelco 37 Component FAME Mix, Merck, Auckland, NZ) using ChemStation software 
(Agilent, Auckland, NZ). Nitrogen was the carrier gas.  
 
4.6 Pharmacokinetics calculation and statistical analyses 
The following PK parameters were calculated for EPA, DHA, n-3 LC PUFA and EPA+DHA plasma 
concentrations out to 12 and 48 hours using a non-compartmental model. 
 AUC0-t: The area under the plasma concentration-time curve, from time t=0 to 12 and 48 
hours, calculated by the linear trapezoidal method.  
 CMax: Maximum measured plasma concentration from time 0 to 12 and 48 hours. 
 TMax: Time of the maximum measured plasma concentration to 12 and 48 hours. 
 t½: A measure of elimination, half-life is the time necessary for the concentration in the 
plasma to decrease by half. 
If the maximum value occurred at more than one time point, TMax was defined as the first time 
point with this value. The plasma concentrations were not baseline adjusted for the PK calculations as 
the concentration changes for all four analytes showed considerable variability after dosing with some 
participants increasing and other decreasing. 
Arithmetic means and standard deviations were calculated for the AUC and CMax parameters and 
medians and inter-quartile ranges (IQR) for TMax. Additionally, geometric means and 95% confidence 
intervals were calculated for AUC and CMax.  
ANOVA was performed for the AUC and CMax parameters to 12 and 48 hours for EPA, DHA, and 
n-3 LC PUFA. These parameters were ln-transformed prior to analysis. The ANOVA model included 
treatment and period (time) as fixed effects, and participant as a random effect. The ANOVA included 
calculation of least-squares means (LSM), and the differences between LSMs and the 95% confidence 
intervals for these differences. These differences and confidence intervals were back-transformed to 
produce geometric mean ratios and 95% confidence intervals.  
The TMax parameters were compared between treatments using Friedman’s non-parametric 
ANOVA with pair-wise comparisons between treatments undertaken when the Friedman’s test 
indicated a significant difference amongst the treatments.  
 
A two-tailed p-value <0.05 was taken to indicate statistical significance. The multiple comparison 
strategy used an approach called Fisher’s protected LSD, this means that only when the f-ratio from the 
ANOVA as significant were the pairwise tests undertaken.  
 
5. Conclusions 
Based on this exploratory study of EPA, DHA and n-3 LC PUFA pharmacokinetic parameters we 
conclude: EPA peak concentrations and plasma exposures were significantly lower with GSM oil 
compared with GSM half-shell and GSM powder products, DHA and n-3 LC PUFA plasma exposure 
parameters were statistically comparable across the four GSM products evaluated and GSM oil 
produced the shortest median time to maximal plasma n-3 LC PUFA concentration of all evaluated 
products. This was primarily due to maximal concentrations being reached during the first peak in 
plasma concentrations, in contrast with the other evaluated products. All products evaluated were 
well-tolerated, with no adverse effects assessed. 
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